Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Free cash flow margin
Gilead Sciences, Inc.'s free cash flow margin over the twelve months to 30 June 2026 was 42.5%, up 10.4 percentage points from fiscal 2025 (32.1%). Over the past ten years it has ranged from 27.4% (fiscal 2023) to 62.8% (fiscal 2015); the current reading is higher than 36% of that period. That is above the Drug Manufacturers General industry median of 17.3% and above the Healthcare sector median of 0.00%.
Free cash flow margin, annual
Annual
| Period | Free cash flow margin | Change (points) |
|---|---|---|
| FY2025 | 32.1% | (3.72) |
| FY2024 | 35.8% | 8.47 |
| FY2023 | 27.4% | (3.22) |
| FY2022 | 30.6% | (8.98) |
| FY2021 | 39.6% | 9.12 |
| FY2020 | 30.5% | (6.61) |
| FY2019 | 37.1% | 3.27 |
| FY2018 | 33.8% | (9.52) |
| FY2017 | 43.3% | (10.32) |
| FY2016 | 53.6% | (9.19) |
Against its own ten years
Low 27.4%
High 62.8%
Ten-year median
35.8%
Current reading's percentile
36
Free cash flow margin against peers
| Company | Free cash flow margin |
|---|---|
| GILD Gilead Sciences, Inc. | 42.5% |
| NVS Novartis AG compare | 26.8% |
| AMGN Amgen Inc. compare | 26.7% |
| SNY Sanofi compare | 25.5% |
| BMY Bristol Myers Squibb Company compare | 23.3% |
| PFE Pfizer Inc. compare | 17.3% |
| GSK GSK PLC Sponsored ADR compare | 17.2% |
| NVO Novo Nordisk A/S compare | 14.8% |
| AZN AstraZeneca PLC compare | 10.2% |
| Drug Manufacturers General industry median | 17.3% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Free cash flow margin is
Free Cash Flow Margin tells an investor how much of each sale turns into cash the company keeps after paying for investment in its assets.
(Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)) ÷ Revenue
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement